For example, aberrant activation of oncogenic signaling pathways including Ras/MAPK, PI3K/AKT/mTOR or loss of function of cancer suppressor genes like p53 which could promote the expression of glucose transporters and glycolytic enzymes [30–32]. This evidence concerns the gene MTOR and cancer.